Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/ soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis. COX-2 inhibitors, which block the formation of prostaglandins, suppress tumor growth, whereas sEH inhibitors, which increase endogenous EETs, stimulate primary tumor growth and metastasis. However, the functional interactions of these two pathways in cancer are unknown. Using pharmacological inhibitors as probes, we show here that dual inhibition of COX-2 and sEH synergistically inhibits primary tumor growth and metastasis by suppressing tumor angiogenesis. COX-2/sEH dual pharmacological inhibitors also potently suppress primary tumor growth and metastasis by inhibiting tumor angiogenesis via selective inhibition of endothelial cell proliferation. These results demonstrate a critical interaction of these two lipid metabolism pathways on tumorigenesis and suggest dual inhibition of COX-2 and sEH as a potential therapeutic strategy for cancer therapy. L ipid signaling in the arachidonic acid (ARA) cascade is an important therapeutic target for many human disorders (1-3). Nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2-selective inhibitors (coxibs), which block COX-2-mediated conversion of ARA to prostaglandin E 2 (PGE 2 ), are widely used to treat inflammation and pain (4). Besides the COX pathway, ARA is also a substrate of cytochrome P450 (CYP) epoxygenases (largely CYP2C and CYP2J), which convert it to epoxyeicosatrienoic acids (EETs) (3). EETs have been investigated as autocrine and paracrine mediators with antihypertensive, anti-inflammatory, analgesic, and cardioprotective effects (5). Although chemically stable, EETs are unstable in vivo due to their rapid metabolism by soluble epoxide hydrolase (sEH) to form dihydroxyeicosatrienoic acids (DHETs), which are usually less active or inactive (5). Pharmacological inhibitors of sEH (sEHIs) that stabilize endogenous EETs are currently being explored as therapeutics (6).
Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/ soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis. COX-2 inhibitors, which block the formation of prostaglandins, suppress tumor growth, whereas sEH inhibitors, which increase endogenous EETs, stimulate primary tumor growth and metastasis. However, the functional interactions of these two pathways in cancer are unknown. Using pharmacological inhibitors as probes, we show here that dual inhibition of COX-2 and sEH synergistically inhibits primary tumor growth and metastasis by suppressing tumor angiogenesis. COX-2/sEH dual pharmacological inhibitors also potently suppress primary tumor growth and metastasis by inhibiting tumor angiogenesis via selective inhibition of endothelial cell proliferation. These results demonstrate a critical interaction of these two lipid metabolism pathways on tumorigenesis and suggest dual inhibition of COX-2 and sEH as a potential therapeutic strategy for cancer therapy. L ipid signaling in the arachidonic acid (ARA) cascade is an important therapeutic target for many human disorders (1) (2) (3) . Nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2-selective inhibitors (coxibs), which block COX-2-mediated conversion of ARA to prostaglandin E 2 (PGE 2 ), are widely used to treat inflammation and pain (4) . Besides the COX pathway, ARA is also a substrate of cytochrome P450 (CYP) epoxygenases (largely CYP2C and CYP2J), which convert it to epoxyeicosatrienoic acids (EETs) (3) . EETs have been investigated as autocrine and paracrine mediators with antihypertensive, anti-inflammatory, analgesic, and cardioprotective effects (5) . Although chemically stable, EETs are unstable in vivo due to their rapid metabolism by soluble epoxide hydrolase (sEH) to form dihydroxyeicosatrienoic acids (DHETs), which are usually less active or inactive (5) . Pharmacological inhibitors of sEH (sEHIs) that stabilize endogenous EETs are currently being explored as therapeutics (6) .
Our previous studies in murine models demonstrated powerful interactions of COX-2 and sEH pathways on pain and inflammation. Pharmacological inhibition of sEH or mice with global disruption of the gene that encodes sEH (sEH-null) synergized with multiple COX inhibitors (including NSAIDs, coxibs, and aspirin) to suppress inflammation and pain with reduced cardiovascular toxicity (7, 8) . Due to the potent synergistic interactions, we recently designed and synthesized the first-in-class, to our knowledge, COX-2/sEH dual pharmacological inhibitors, which concurrently inhibit both COX-2 and sEH enzymes (9) . A COX-2/sEH dual inhibitor, 4-(5-phenyl-3-{3-[3-(4-trifluoromethylphenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide (PTUPB), as illustrated in Fig. S1 , is more efficacious in attenuating inflammatory pain in vivo than celecoxib (a coxib) alone, trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) (a selective sEHI) alone, or the combination of both celecoxib and t-AUCB (9) . Coadministration of COX-2 and sEH inhibitors or administration of a dual inhibitor acts to reduce proinflammatory eicosanoids, such as PGE 2 , and to increase anti-inflammatory and cardioprotective eicosanoids, such as EETs (Fig. S1B) . Together, these results support the potent interactions of these two lipid metabolism pathways.
Recent studies have demonstrated that both COX-2 and sEH play critical roles in angiogenesis and tumorigenesis (5, (10) (11) (12) (13) . Epidemiological and clinical evidence supports that COX-2 inhibitors inhibit multiple cancers (13) . Contrary to the antitumor activity of COX-2 inhibitors, we and others have shown that when administered at the high dose of 10 mg·kg −1 ·d −1 , sEHIs stimulate primary tumor growth and metastasis via EETs (11, 12, 14) . Unexpectedly, we now demonstrate that a combination of a low-dose COX-2 inhibitor and a low-dose sEHI (3 mg·kg −1 ·d −1 ) synergistically inhibits primary tumor growth and metastasis. We extend this result by showing that the COX-2/sEH dual inhibitors also potently inhibit primary tumor growth and metastasis via suppressing tumor angiogenesis. These results support a key interaction of these two pathways on cancer progression.
Significance
Our study suggests that cyclooxygenase (COX)-2 and soluble epoxide hydrolase (sEH) pathways have potent synergistic antiangiogenic and anticancer activity. Dual pharmacological inhibition of COX-2 and sEH pathways may be useful in treating cancer with minimal toxicity associated with COX-2 inhibition. ) had minimal activity on tumor growth, whereas celecoxib alone (30 mg·kg
) inhibited tumor growth by 42%. Unexpectedly, the combination of t-AUCB and celecoxib markedly inhibited LLC growth by 79% (Fig. 1A) . For tumor metastasis, we used a well-established LLC resection model in which resection of the primary LLC tumor triggers spontaneous lung metastasis due to reduced levels of circulating angiogenesis inhibitors derived from the primary tumors (11, 15, 16) . Treatment with t-AUCB (3 mg·kg −1 ·d −1 ) or celecoxib (30 mg·kg −1 ·d −1 ) alone had no effect on LLC metastasis, whereas coadministration of both compounds resulted in a dramatic 71-74% reduction in surface metastatic foci and lung weight, a surrogate marker of metastatic burden (Fig. 1B) . Together, these results support the potent synergistic antitumor effect of sEHI and coxib on primary tumor growth and metastasis.
Because primary tumor growth and metastasis are angiogenesis-dependent (17), we next studied whether coadministration of sEHI and coxib synergistically suppressed angiogenesis. The combination of low-dose t-AUCB and celecoxib synergistically inhibited endothelial cell proliferation in vitro (Fig. S2) , supporting an antiangiogenic mechanism.
COX-2/sEH Dual Inhibitor PTUPB Inhibits Angiogenesis. Combination therapy is often challenging because of poor patient compliance, complicated drug-drug interactions, or patient-dependent differences in the pharmacokinetic (PK) profiles of each drug (18) . To investigate the synergistic interactions of COX-2 and sEH on cancer further, we studied the role of the COX-2/sEH dual pharmacological inhibitors in angiogenesis and cancer. A dual inhibitor, PTUPB, inhibits sEH with IC 50 = 0.9 nM, which is comparable to the selective sEHIs developed in our laboratory (19) . It is a COX-2-selective inhibitor with IC 50 = 1.26 μM for COX-2 and IC 50 > 100 μM for COX-1, and it is more potent than rofecoxib (Vioxx) and indomethacin (Indocin) for COX-2 inhibition (9). In addition, it possesses adequate PK properties (PK data in Fig. S1C and Table S1 ); thus, we have selected PTUPB as our probe.
PTUPB inhibited endothelial tube formation ( Fig. 2A ) and aortic vessel sprouting (Fig. S3A ) in a dose-dependent manner. In a Matrigel (BD Biosciences) plug assay in mice (20) , PTUPB inhibited VEGF-induced angiogenesis by 85% after 4 d of treatment (Fig. 2B) . Thus, PTUPB is antiangiogenic in vitro and in vivo. The process of angiogenesis involves multiple cellular steps, including endothelial cell migration, proliferation, and production of matrix metalloproteinases (MMPs) (21) . Therefore, we further characterized the antiangiogenic activity of PTUPB. PTUPB had no effect on endothelial cell migration or MMP activity ( Fig. S3 B-D), although it specifically inhibited endothelial cell proliferation more potently than celecoxib alone, 1-trifluoromethoxyphe-nyl-3-(1-propionylpiperidin-4-yl)urea (TPPU, a selective sEHI) alone, or a combination of both (Fig.  2C ). Interestingly, PTUPB had minimal inhibitory activity on cancer cell proliferation, including human prostate cancer (PC-3), human melanoma (H-1 and A375), and mouse breast cancer (Met-1), as well as a transformed endothelial cell line (bEnd.3), after a 3 d of treatment (Fig. 2D ). This conclusion was further supported by a National Cancer Institute-60 human cancer cell line screening showing that PTUPB had minimal inhibitory effects on cell proliferation in most of the 60 human cancer cell lines (Fig. S4A ). Besides PTUPB, other dual inhibitors synthesized also specifically inhibited endothelial cell proliferation ( Fig. S4 B and C). Because VEGF receptor 2 (VEGFR2) is a critical mediator of angiogenesis and cancer (22, 23) , we studied whether PTUPB inhibited angiogenesis via a VEGFR2-dependent mechanism. PTUPB at 10 μM had no inhibition not only on VEGFR2 kinase activity in a cell-free VEGFR2 kinase assay (Fig. S4D ) but also on VEGF-induced VEGFR2 phosphorylation in human umbilical vein endothelial cells (HUVECs) (Fig. S4E ), suggesting n.s. that PTUPB does not inhibit angiogenesis by altering VEGFR2 signaling.
Because PTUPB inhibited endothelial cell proliferation, we analyzed the effect of PTUPB on cell cycle in endothelial cells. Cell cycle analysis showed that PTUPB induced cell cycle arrest at the G0/1 phase (Fig. 2E) . Cyclin D1 and cyclin-dependent kinase 4 (CDK4) or cyclin-dependent kinase 6 (CDK6) complex promotes the G1-S transition, whereas p53 family proteins, including p21 and p27, whose transcription is regulated by p53, inhibit the G1-S transition by binding the complexes (24) . PTUPB at 10-20 μM attenuated levels of CDK4 and CDK6 proteins in a dose-dependent manner after a 24-h treatment in HUVECs (Fig. 2F) , whereas cyclin D1 and p53 levels were not affected (Fig. S4F) , demonstrating that PTUPB caused cell cycle arrest at the G0/1 phase via inhibition of CDK4 and CDK6.
COX-2/sEH Dual Inhibitor PTUPB Inhibits Primary Tumor Growth and
Metastasis. For primary tumor growth, dual inhibition of COX-2 and sEH by systematic administration of 30 mg·kg −1 ·d −1 of PTUPB inhibited NDL and LLC tumor growth by 70-83% (Fig.  3A and Fig. S5A ). PTUPB exhibited no overt toxicity, such as any weight loss, compared with the control group (Fig. S5B) . PTUPB treatment significantly suppressed CD31-positive endothelium in NDL tumors and the plasma level of VEGF ( Fig. 3 B and C) , demonstrating that PTUPB inhibits tumor angiogenesis. To study tumor metastasis, we used the primary tumor (LLC) resection metastasis model (11, 15, 16) . PTUPB treatment for 14 d resulted in potent suppression of surface metastatic foci and lung weight by 61-67% (Fig. 3D) . The efficacy of PTUPB on inhibition of primary tumor growth and metastasis is comparable to the coadministration of celecoxib and t-AUCB in the LLC model (Fig. 1) . The dose of PTUPB in the tumor experiments was determined to be 30 mg·kg −1 ·d −1 on the basis of a doseresponse PK study, which showed that at a dose of ∼30 mg/kg, the peak plasma concentration of PTUPB was above its IC 50 value for COX-2 ( Fig. S1C and Table S1 ).
Pharmacological Target Engagement of Dual Inhibitor PTUPB. To test whether inhibition of COX-2 and sEH pathways is involved in the mode of action of PTUPB in vivo, we analyzed eicosanoid profiles using LC-tandem MS-based lipidomics (25) . PTUPB treatment reduced PGE 2 in plasma by ∼55% (P < 0.001), indicating that PTUPB inhibited the COX-2 pathway in vivo (Fig.  3E ). For the CYP/sEH pathway, PTUPB treatment caused an approximately threefold increase of 11,12-EET and 14,15-EET in NDL tumors, whereas it had no effect on the corresponding diol metabolites 11,12-DHET and 14,15-DHET (Fig. 3F) . PTUPB increased the ratio of 5,6-EET to its sEH metabolite 5,6-DHET by 43% and the ratio of 10,11-epoxydocosapentaenoic acid (EDP) to its sEH metabolite 10,11-dihydroxydocosapentaenoic acid (DiHDPA) by 97% in plasma (Fig. S6) . Together, these results indicate that PTUPB inhibited the sEH pathway in vivo. The lipid mediators from other pathways were not significantly changed (Table S2) . Together, these data support that PTUPB inhibits both COX-2 and sEH, although it may have effects on other cellular targets.
A major theory to explain the potential cardiovascular risks of coxibs is that they block the formation of prostacyclin (PGI 2 ), which is a potent vasodilator, but not COX-1-derived thromboxane A 2 (TXA 2 ), which is a potent vasoconstrictor; therefore, a decrease of the PGI 2 -to-TXA 2 ratio may increase the incidence of thrombotic cardiovascular events (26) . Consistent with this theory, our previous study showed that a 6-h treatment with either celecoxib or rofecoxib significantly reduced the ratio of PGI 2 [by measuring its stable metabolite 6-keto prostaglandin F 1α (6-keto-PGF 1α )] to TXA 2 (by measuring its stable metabolite TXB 2 ) in plasma in mice (7) . Even though PTUPB is also a selective COX-2 inhibitor (IC 50 for COX-2 = 1.26 μM, IC 50 for COX-1 > 100 μM), the ratio of PGI 2 to TXA 2 in plasma was not significantly altered after a 26-d treatment with PTUPB ( Fig. 3G) , suggesting that PTUPB may have reduced cardiovascular risks compared with coxibs, such as celecoxib or rofecoxib.
Discussion COX inhibitors and sEHIs reduce inflammation and pain (4, 27, 28) . We previously demonstrated that a combination of sEHIs [such as 12-(3-adamantan-1-yl-ureido)-dodecanoic acid n-butyl ester (AUDA-nBE) or t-AUCB] and COX inhibitors (indomethacin, celecoxib, rofecoxib, or aspirin) synergistically inhibited LPS-induced inflammation and pain in mice (7, 8) . Studies in sEH-null mice also show that interaction with aspirin suppresses LPS-induced inflammation and hypotension (8) . These results support the potent interactions of these two pathways. One possible mechanism to explain the interactions of COX-2 and sEH pathways is a reduction of PGE 2 . In an LPS-induced murine inflammation model, we have shown that coadministration of sEHI and COX inhibitors dramatically reduced circulating PGE 2 (7, 8) . The reduction of PGE 2 is likely due to both inhibition of COX-2 transcription by sEH inhibition and inhibition of COX-2 enzymatic activity by COX inhibitors (29) . PGE 2 has potent proangiogenic, proinflammatory, and protumorigenic effects (13); therefore, a dramatic reduction of PGE 2 may, in part, mediate the effects of the dual inhibition of sEH and COX-2.
We previously demonstrated that high-dose sEHI t-AUCB (10 mg·kg
) increased primary tumor growth and metastasis by stimulating tumor angiogenesis and VEGF levels (11) but lowdose t-AUCB (1 mg·kg −1 ·d −1 ) inhibited LLC metastasis by 31% (P = 0.057) (12) . We now show that t-AUCB alone at 3 mg·kg
has no effect on primary tumor growth and metastasis. Importantly, the combination of low-dose sEHI t-AUCB and the COX-2 inhibitor celecoxib synergistically suppresses primary tumor growth and metastasis. Our primary tumor and metastasis studies with the COX-2/sEH dual inhibitor PTUPB further supported these results. It appears that sEH inhibition or EETs have biphasic dose-dependent activity on angiogenesis, primary tumor growth, and metastasis. In fact, several angiogenesis modulators, such as α-IFN, endostatin, rosiglitazone, statins, chemotherapy (e.g., 5-fluorouracil, cisplatinum), bortezomib, enterostatin, integrin inhibitors, plasminogen activator-1, rapamycin, thrombospondin-1, TGF-α1, and TGF-α3, have been shown to exhibit a biphasic, U-shaped, or J-shaped dose-efficacy curve known as hormesis (16, 17, (30) (31) (32) (33) (34) . The sEHIs may be an addition to this growing class of angiogenesis modulators that exhibit a hormesis response. Coxibs have anti-inflammatory and antiangiogenic activity on tumor growth (13) . Low-dose sEHIs may further sensitize the anti-inflammatory and antiangiogenic effects of COX-2 inhibition. Our previous studies, as well as those of others, have demonstrated that the proangiogenic and protumorigenic effects of EETs require VEGF. For example, blocking the VEGF pathway abolishes the proangiogenic and protumorigenic effects of EETs (11, (35) (36) (37) . COX-2 inhibition has been shown to inhibit VEGF production (38); thus, coinhibition of COX-2 may reduce or eliminate the proangiogenic effects of EETs. As expected here, we also found that PTUPB reduced the plasma VEGF level by 50%. The reduction of VEGF and PGE 2 and the stabilization of anti-inflammatory EETs are consistent with the observed effects.
Importantly, we show that COX-2/sEH dual inhibitors are selective inhibitors of endothelial cell proliferation. We screened over 60 different cell lines and found that only HUVECs (a primary endothelial cell line) were highly sensitive to the antiproliferative effect of PTUPB. Few such selective inhibitors of endothelial proliferation have been discovered; other examples include TNP-470 (39), rosiglitazone (16) , cytochalasin E (40) and cortistatin A (41) . TNP-470 is, to our knowledge, the first synthetic angiogenesis inhibitor to be discovered, and it has been intensively characterized (39) (42) . TNP-470 inhibited endothelial cell proliferation via cell cycle arrest at the G1 phase (42); however, the mechanism by which it selectively inhibits endothelial cell proliferation is not well understood (43, 44) . Here, we find that PTUPB arrested the cell cycle at the G0/1 phase via a mechanism involving inhibition of CDK4 and CDK6 in HUVECs and that it did not inhibit VEGFR2 signaling.
The COX-2/sEH dual inhibitors were designed and optimized using in vitro enzymatic assays of COX-1, COX-2, and sEH (9) . Here, we provide in vivo evidence that systematic administration of PTUPB decreased PGE 2 and increased EETs (and other fatty acid epoxides) in mice, with minimal alteration of other lipid mediators, supporting the pharmacological targets by the selective dual inhibition of both COX-2 and sEH. An early sepsis study showed that in addition to the expected changes in the P450 metabolites, inflammatory COX-derived metabolites were reduced by the sEHIs. At higher doses, the sEHIs also reduced inflammatory lipoxygenase (LOX)-derived metabolites (27) . In an LPS-induced inflammation and pain model, inhibition of sEH reduced levels of LOX, as well as P450 and COX metabolites. This reduction in pain and inflammation was enhanced by coinhibition of the 5-LOX pathway (8) . However, using lower doses of sEHIs, we did not observe changes in LOX metabolites. Dual inhibition with low doses of COX-2 and sEHIs synergistically inhibited COX-2-derived eicosanoids, such as PGE 2 , but did not alter LOX metabolites (7, 8) . Thus, it was not surprising that the low-dose dual inhibitor PTUPB used in this study did not alter the levels of LOX-derived eicosanoids in plasma and tumor tissues. Although we show that PTUPB inhibits COX-2 and sEH, it may have other targets. Looking forward, the chemical scaffold of PTUPB provides a starting point for further structural modification of COX-2/sEH dual inhibitors to optimize its PK profile (9). Due to its poor oral bioavailability, we continuously infused PTUPB into mice in tumor experiments using an osmotic minipump to test the concept of dual inhibition of COX-2 and sEH. Further structural optimization using medicinal chemistry could improve its PK profile for oral administration. In addition, if inhibition of both COX-1 and COX-2 enzymes is required, these properties could be designed into the molecule. PTUPB is a dramatically more potent sEHI than COX-2 inhibitor. Some selectivity in favor of sEH is desirable because complete inhibition of an enzyme degrading an apparently beneficial lipid mediator is attractive (5) . Also, the sEHIs studied to date appear to have a massive therapeutic index compared with a more limited one with COX inhibitors (19) . More potent COX inhibition may be desirable; however, this could be challenging because in vitro COX assays correlate weakly with in vivo efficacy (4) and PTUPB is already more potent than many marketed NSAIDs and coxibs for COX-2 inhibition (9) .
In conclusion, our study suggests that COX-2 and sEH pathways have potent interactions on angiogenesis and cancer. Dual pharmacological inhibition of COX-2 and sEH pathways is a promising therapeutic approach to treating cancer with minimal toxicity. ) by oral gavage (n = 4-5 mice per group, drugs were dissolved in 0.45% methylcellulose). Tumor sizing was measured by a caliper. For the NDL tumor model, NDL breast tumor pieces (1 mm 3 ) were transplanted into the fourth inguinal mammary fat pads of FVB female mice. After 8 d of tumor implantation, the mice were randomized to two groups (n = 6 mice per group) and treated with PTUPB (30 mg·kg , LLC tumors were resected and PTUPB or vehicle pumps were implanted. The mice were euthanized on day 14 postresection, and lungs were evaluated for weight and number of surface metastases as described (11, 15, 16) .
Materials and Methods

Details
Statistics. Group comparisons were carried out using one-way ANOVA or the Student t test. A P value less than 0.05 was considered statistically significant. Data are presented as mean ± SD. A cyclooxygenase (COX)-2/soluble epoxide hydrolase (sEH) dual inhibitor 4-(5-phenyl-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide (PTUPB) and other COX-2/sEH dual inhibitors were synthesized as described (1) . Two sEH inhibitors (sEHIs) of quite different structures but similar potency on the affinity-purified murine recombinant sEH were used in the study to test the hypothesis that the sEHI effects were due to sEH inhibition and were not just structure-dependent. The two sEHIs are trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) (2) and 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU) (3). The structures of the compounds were supported by NMR, IR, and MS, and high purity was indicated by TLC, HPLC-MS, and the melting point.
Cell Proliferation Assay. The cells were plated into 96-well plates at a cell density of 1-1.5 × 10 3 cells per well in 100 μL of complete medium. After 24 h, the medium was replaced with fresh medium containing test compounds. After 72 h of treatment, cell viability was assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) or BrdU assay (Millipore). PTUPB was also subjected to a National Cancer Institute-60 human cancer cell line screening, in which the cancer cells were treated with PTUPB for 48 h.
Tube Formation Assay. The 96-well plates were coated with 35 μL per well of growth factor-reduced Matrigel (BD Biosciences) and solidified at 37°C for 30 min; 1.5-2 × 10 4 HUVECs in 100 μL of basal medium were then added to each well. After 6 h of treatment, microscope images were recorded (4).
Mouse Aortic Ring Assay. The aortas of C57BL/6 mice were dissected, washed with serum-free F-12K medium five to six times, and then cut to ∼1-mm length rings. The aortic rings were placed in 48-well plates that were precoated with 100 μL per well of growth factor-reduced Matrigel and incubated at 37°C for 10 min; another 100 μL of Matrigel was then added into each well and solidified at 37°C for 30 min. Complete endothelial culture medium (500 μL) containing test compounds was added into each well. After 4-8 d of treatment, microscopic images were recorded (5).
Oris Cell Migration Assay. HUVECs were plated into 96-well plates (Platypus Technologies) with stoppers at a cell density of 2 × 10 4 cells per well in 100 μL of complete endothelial medium. After 24 h, the stoppers were removed, the medium was decanted, and the wells were washed using PBS buffer and treated with test compounds in complete medium. After 24 h of treatment, the cells were stained with Calcein AM (Caymen Chemicals) and fluorescence microscope images were recorded.
Boyden Chamber Cell Migration Assay. HUVECs or LLC cancer cells (5 × 10 4 cells per well) were seeded onto the upper chamber of cell culture inserts for a 24-well plate containing membrane with 8-μm pores (BD Biosciences) in 400 μL of serum-free medium, and the bottom chamber was filled with 500 μL of complete medium as chemoattractant. The test compounds were added into both the top and bottom chambers. After 18-24 h of incubation, the inserts were washed with PBS and fixed with 5% glutaraldehyde for 30 min, and the unmigrated cells were removed with cotton swabs. The migrated cells were stained with crystal violet, and microscope images were recorded and migrated cells were counted using ImageJ (National Institutes of Health) software (6).
Gelatin Zymography. HUVECs were seeded in six-well plates in complete endothelial medium and allowed to attach overnight, and the cells were then treated with test compounds for 24-72 h. Matrix metalloproteinase activities in the cell culture medium were analyzed by zymography using Novex 10% Zymogram (Gelatin) Gel (Invitrogen).
Immunoblotting. For cell cycle analysis, HUVECs in six-well plates were treated with PTUPB for 24 h. For VEGF receptor 2 (VEGFR2) signaling, HUVECs were serum-starved in basal medium for 24 h and then treated with 50 ng/mL VEGF and PTUPB for 10 min. The medium was decanted and washed with cold PBS buffer; the cells were then lysed and the cell lysates were resolved using SDS/PAGE and transferred onto a nitrocellulose membrane. The membranes were blocked in 5% nonfat dry milk for 1 h at room temperature and probed with mouse monoclonal anti-cyclindependent kinase 4 (CDK4) and anti-cyclin-dependent kinase 6 (CDK6) antibodies (Cell Signaling Technology), mouse monoclonal anti-p53 antibody (Santa Cruz Biotechnology Inc.), rabbit polyclonal anti-cyclin D1 antibody (Cell Signaling Technology), anti-p-VEGFR2 antibodies (Cell Signaling Technology), and mouse monoclonal anti-β-actin antibody (Sigma-Aldrich). The membranes were then probed with HRP-tagged secondary antibodies. The secondary antibodies on the blot were detected by an ECL Plus Western Blotting Detection Reagent (GE Healthcare).
Cell Cycle Analysis. HUVECs were treated with PTUPB for 24 h in flasks. After treatment, the cells were collected, washed with cold PBS, and fixed in 70% ethanol at −20°C for at least 3 h. The cells were then washed with PBS and stained with propidium iodide. After staining, the cells were processed for cell cycle analysis using Muse Cell Analyzer from Millipore following the manufacturer's instructions.
Matrigel Plug Angiogenesis Assay. All procedures and animal care were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committee of the University of California, Davis. A total of 0.5 mL of growth factor-reduced Matrigel was mixed with 100 ng of mouse VEGF 164 (R&D Systems) and 20 units of heparin (APP Pharmaceuticals), with or without PTUPB. The gel was then s.c. injected into C57BL/6 mice in the abdominal area. After 4 d, the animals were euthanized to dissect the implanted Matrigel plugs. The gel plugs were weighed, homogenized in 1 mL of PBS buffer, and centrifuged, and the content of hemoglobin in the supernatant was analyzed using Drabkin's reagent (Sigma-Aldrich) and normalized to the gel weights. Endothelial cell invasion into the gel plugs were characterized by the immunohistochemistry of CD31 staining (7).
Lipidomics. For plasma lipid mediator extraction, Waters Oasis solid phase extraction (SPE) cartridges were prewashed, and 250 μL of plasma with surrogate solution was loaded onto the SPE column and washed with 95:5 (vol/vol) water/methanol with 0.1% acetic acid. The analytes were eluted with methanol and ethyl acetate, dried, and then reconstituted in methanol for LC-tandem MS (MS/MS) analysis. For tumor lipid mediator extraction, ∼100 mg of tumor tissues was mixed with the antioxidant solution (0.2 mg/mL butylated hydroxytoluene and 0.2 mg/mL triphenylphosphine in methanol), the surrogate solution, and 400 μL of extract solution (0.1% acetic acid with 0.2 mg/mL butylated hydroxytoluene in a methanol solution), and then homogenized; the resulting homogenates were kept at −80°overnight. After centrifugation of the homogenates, the pellets were washed with methanol with 0.1% butylated hydroxytoluene and 0.1% acetic acid, and then combined with the supernatant. The combined solutions were extracted using SPE columns as described above. The LC-MS/MS analysis was carried out on an Agilent 1200SL liquid chromatographic system coupled to a 4000 QTRAP MS/MS instrument (AB Sciex) as described (8) . In a cell-free KinaseSeeker assay, PTUPB at 10 μM had a minimal effect to inhibit VEGFR2 kinase activity, although the positive control sorafenib at 10 μM inhibited 100% of the kinase activity. This assay was carried out by Luceome Biotechnologies. (E) PTUPB at 10 μM had no effect on inhibition of VEGF-induced VEGFR2 phosphorylation (phosphorylation at Tyr1175 or Tyr951 of VEGFR2) in HUVECs. HUVECs were serum-starved for 24 h and then treated with 50 ng/mL VEGF and 10 μM PTUPB for 10 min, followed by Western blot analysis. (F) PTUPB had little effect on expression of p53 and Cyclin D1 after 24 h of treatment in HUVECs. The results are expressed as mean ± SD. *P < 0.05; **P < 0.01. 
